Neurocristopathy: Its growth and development in 20 years

Pediatric Pathology and Laboratory Medicine

Volumn 17, Issue 1, 1997, Pages 1-25

  Bolande, Robert P ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

diseases; malformations; neoplasms; neural crest

Indexed keywords

MUTAGENIC AGENT; TERATOGENIC AGENT;

ARTICLE; DIGEORGE SYNDROME; HIRSCHSPRUNG DISEASE; MOLECULAR GENETICS; NEOPLASM; NEURAL CREST; ONTOGENY; PATHOLOGY; PIGMENT DISORDER; PRIORITY JOURNAL; SYNDROME; WAARDENBURG SYNDROME;

EID: 0031030433     PISSN: 10771042     EISSN: None     Source Type: Journal    
DOI: 10.1080/15513819709168343     Document Type: Article

References (145)

1. Rolande R. The neurocristopathies. A unifying concept of disease arising in neural crest maldevelopment. Hum Pathol 1974;5:409-20.
2. Hörstadius S. The Neural Crest. Its Properties and Derivatives in the Light of Experimental Methods. Oxford: Oxford University Press, 1950.
3. WestonJ. The migration and differentiation of neural crest cells. Adv Morphog 1970;8:41-114.
4. His W. Untersuchungen ueber die erste Anlage der Wirtbeltierleibes die erste Entwickelung des Münchens im Ei. Leipzig: Vogel, 1868.
5. Weston JA. Motile and social behavior ofneural crest cells. In: Bellairs R, Curtis A, Dünn C, eds. Cell Behaviour. Cambridge: Cambridge University Press, 1982;429-70.
6. LeDouarin N. The Neural Crest. Cambridge: Cambridge University Press, 1982.
7. Bronner-Fraser M. Neural crest formation and migration in the developing embryo. FASEB J 1994;8:699-706.
8. Newgreen DF, Erickson CA. The migration of neural crest cells. Int Rev Cytol 1986; 103:89-145.
9. LeDouarin N. Cell line segregation during peripheral nervous system ontogeny. Science 1986;231: 1515-22.
10. Noden DM. Origin and patterning of craniofacial mesenchymal tissues. J Oraniofac Genet Dev Biol 1986;2:15-31.
11. Newgreen, DF, Thiéry J-P. Fibronectin in early avian embryos: Synthesis and distribution along migration pathways of neural crest cells. Cell Tissue Res 1980;211:269-96.
12. Tucker GO, DubandJ-L, Dufour S, Thiéry J-P. Cell-adhesion and substrate-adhesion molecules: Their instructive role in neural crest migration. Development 1988;103(Suppl):81-94.
13. Erickson C, Perris R. The role of cell-cell adhesion and cell-matrix interactions in the morphogenesis of the neural crest. Dev Biol 1993;159:60-74.
14. Redline RW, Neish A, Holmes L, Collins T. Homeobox genes and congenital malformations. Lab Invest 1992;6:659-70.
15. Gendron-Maguire M, Mallo M, Zhang M, Gridley T. Hoxa-2 mutant mice exhibit homeotic transformation of skeletal elements derived from cranial crest. Cell 1993;75:1317-31.
16. Manley R, Capecchi MR. The role of Hoxa-3 in mouse thymus and thyroid development. Development 1995;121:1989-2003.
17. Nakagawa S, Takeichi M. Neural crest cell-cell adhesion controlled by sequential and subpopulation specific expression of novel cadherins. J Embryol Exp Morphol 1984;84:49-62.
18. Ito K, Takeuchi T. The differentiation in vitro of the neural crest cells of the mouse embryo.J Embryol Exp Morphol 1984;84:49-62.
19. LeDouarin N, Ziller Z, Couly GF. Patterning of neural crest derivatives in the avian embryo: In vivo and in vitro studies. Dev Biol 1993; 154:24-49.
20. Anderson DJ. Molecular control of cell fate in the neural crest: The sympathoadrenal lineage. Annu RevNeurosci 1993;16:129-58.
21. Campuzano S, Modolell J. Patterning of the Drosophila nervous system: the achaett-scute gene complex. Trends Genet 1991;8:202-8.
22. Pachins V, Mankoo B, Constantin! F. Expression of c-ret protooncogene during mouse embryogenesis. Development 1993; 119:1005-17.
23. Nakamura T, Ishizaka Y, Nagao M, Hara M, Ishikawa T. Expression of the ret protooncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol 1994;172:255-60.
24. Greenstein-Banyash A, Hosoda K, Giaid A, et al. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 1994;79: 1277-85.
25. Kissel P, André JM, Jacquier A. The Neurocristopathies. New York: Masson, 1981;19-38, 205-21.
26. Kirby ML, Bockman DE. Neural crest and normal development: A new perspective. Anat Rec 1984;209:l-6.
27. Jones MC. The neurocristopathies: Reinterpretation based upon the mechanism of abnormal morphogenesis. Cleft Palate J 1990;27:136-40.
28. Jackson IJ. Mouse coat color mutations: A molecular genetic resource which spans the centuries. Bioessaysl991;3:439-46.
29. Fleischman RA, Saltman DL, Stastny V, Zneimer S. Deletion of c-kit protooncogene in the human developmental defect piebald trait. Proc Nad Acad Sci USA 1991;88:10885-889.
30. Spritz RA, Giebel LB, Holmes SA. Dominant negative loss of function mutations of the c-kit protooncogene in human piebaldism. AmJ Hum Genet 1991;50:261-9.
31. Ezoe K, Holmes SA, Ho L, et al. Novel mutations and deletions of the KIT (steel factor receptor) gene in human piebaldism. AmJ Hum Genet 1995;56:58-66.
32. Weinberg AG. Hirschsprung's disease-a pathologist's view. Perspect Pediatr Pathol 1975;2:207-39.
33. Badner J, Sieber WK, Garver KL, Chakravarti A. A genetic study of Hirschsprung's disease. AmJ Hum Genet 1990;46:568-80.
34. Munakata K, Okabe I, Morita K. Histologie studies of rectocolic aganglionosis and allied diseases. J Pediatr Surg 1978;3:67-75.
35. Kapur RP. Contemporary approaches toward understanding the pathogenesis of Hirschsprung disease. Pediatr Pathol 1993;13:83-100.
36. Qualman SJ, Murray R. Aganglionosis and related disorders. Hum Pathol 1994;25:1141-49.
37. Nezelof C, Guy-Grand D, Thomine E. Les megacolons avec hyperplasie des plexus myentérique. Presse Med 1970;78:1401.
38. Scharli AF, Meier-Ruge W. Locali/ed and disseminated forms of neuronal intestinal dysplasia mimicking Hirschsprung's disease. J Pediatr Surg 1981;2:184-70.
39. Schofield DE, Yunis EJ. What is intestinal neuronal dysplasia? Pathol Annu 1992;1:249-62.
40. Earlam RJ. A vascular cause for aganglionic bowel; a new hypothesis. AmJ Dig Dis 1972;17:255-61.
41. Bolande RP, Towler WF. Ultrastructural and histochemical studies of murine megacolon. AmJ Pathol 1972:69:139-54.
42. Romeo G, Ronchetto P, Luo Y, étal. Point mutations affecting the tyrosine kinase domain of the RET pi oto-oncogene in Hirschsprung's disease. Nature 1994;367:377-8.
43. Edery P, Lyonnet S, Mulligan LM, et al. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994;367:378-80.
44. Puffenberger EG, Hosoda K, Washington SS, et al. A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Gell 1994;79:1257-66.
45. Hosoda K, Hammer RE, Richardson JA, et al. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 1994:79:1267-76.
46. I,yon MF, Searle AG. Genetic Variants and Strains of the Laboratory Mouse. Oxford: Oxford University Press, 1989.
47. Ikadai H, Fujita H, Agematsu Y, Imamamichi T. Observations of congenital agangliosis in the rat and its genetic analysis. Senten Ijo 1979;9:31-6.
48. McCabe L, Griffin LD, Kinzer A, Chandler M, Beckwith JB, McCabe ERB. Overo lethal white foal syndrome: Equine model of aganglionic megacolon (Hirschsprung disease). AmJ Med Genet 1990:36:336-40.
49. Mahakrishnan A, Srinivasan MS. Piebaldism with Hirschsprung's disease. Arch Dermatol 1980; 116:1102.
50. Shah KN, Dala SJ, Desai MP, Sheth PN, Joshi NC, Ambani LM. White forelock, pigmentary disorder of irides, and long segment Hirschsprung disease: A possible variant of Waardenburg syndrome. J Pediatr 1981:99:432-5.
51. Kaplan P, deChadarévian JP. Piebaldism-Waardenburg syndrome: Histopathologic evidence for a neural crest syndrome. AmJ Hum Genet 1988;31:679-88.
52. Bower RJ, AdkinsJC. Ondine's curse and neurocristopathy. Clin Pediatr 1980;19:665-8.
53. Levard G, Boige N, Vitoux C, Aigrain Y, Boureau M, Navarro J. Neurocristopathy. The association of Hirschsprung's disease-ganglioneuromawith autonomie dysfunction in 2 children. Arch Fr Pediatr 1989;46:595-7.
54. Arroyo-Carrera I, Carretero-Diaz V, Garcia-Garcia MJ, et al. Hirschsprung's disease and primary central hypoventilation. An Esp Pediatr 1993;38:87-9.
55. RutledgeJC. Research advances in prenatal craniofacial development. Pediatr Pathol 1989;9:613-21.
56. Tassabehji M, Read AP, Newton VE, et al. Waardenburg's syndrome patients have mutations in the human homologue of the Pax-3 paired box gene. Nature 1992:355:635-6.
57. Baldwin CT, Hoth CF, Amos JA, da Suva EO, Milunsky A. An exonic mutation in the HuP2 paired domain gene causes Waardenburg's syndrome. Nature 1992;355:637-41.
58. Lalwani AK, Brister JR, Fex J, et al. Further elucidation of the genomic structure of PAX 3 and identification of two different point mutations within the PAX 3 homeobox that cause Waardenburg syndrome type 1 in two families. AmJ Hum Genet 1995;56:75-83.
59. DiGeorge AM. Congenital absence of the thymus and its immunologie consequences: Concurrence with congenital hypoparathyroidism. In: Bergsma D, Good RA, eds. Birth Defects: Immunology Deficiency Diseases in Man. Original articles, series IV. New York: National Foundation-March of Dimes, 1968:116.
60. van Mierop LHS, Kutsche LM. Cardiovascular anomalies in DiGeorge syndrome and the importance of the neural crest as a possible pathogenetic factor. Am [ Cardiol 1986;56:133-7.
61. Robinson HB. DiGeorge's or the III-IV pharyngeal pouch syndrome: Pathology and a theory of pathogenesis. Perspect Pediatr Pathol 1975;2:173-206.
62. Bookman EE, Kirby ML. Dependence of thymus development on derivatives of the neural crest. Science 1984;223:498-500.
63. Burke BA, Johnson D, Gilbert E. Drut RM, LudwigJ, Wick MR. Thyrocalcitonin-containing cells in the DiGeorge anomaly. Hum Pathol 1987; 18:355-60.
64. Patrone PM, Chatten J, Weinberg P. Neuroblastoma and DiGeorge anomaly. Pediatr Pathol 1990; 10:425-30.
65. Driscoll DA, Budarf ML, Emanuel BS. A genetic etiology for DiGeorge syndrome: Consistent deletions and microdeletions of 22ql 1. AmJ Hum Genet 1992;50:924-33.
66. Demczuk S, Desmaze C, Aikem M, et al. Molecular cytogenetic analysis of a series of 23 DiGeorge syndrome patients by fluorescence in situ hybridization. Ann Genet 1994;37:60-5.
67. Driscoll DA, Spinner NB, Budarf ML, et al. Deletions and microdeletions of 22q 11.2 in velo-cardiofacial syndrome. AmJ Hum Genet 1992:44:261-8.
68. Driscoll DA. Genetic basis of DiGeorge and velocardiofacial syndromes. Curr Opin Pediatr 1994; 6:702-6.
69. Halford S, Wadey R, Roberts C., et al. Isolation of a putative transcriptional regulator from the region of 22ql 1 deleted in DiGeorge syndrome, Shprintzen syndrome and familial congenital heart disease. Hum Mol Genet 1993;2:2099-107.
70. Budarf ML, CollinsJ, Gong W, et al. Cloning of a balanced translocation with DiGeorge syndrome and identification of a disrupted candidate gene. Nat Genet 1995; 10:269-78.
71. Berthold F. Overview: Biology of neuroblastoma. In: Pocheldy C, ed. Neuroblastoma: Tumour Biology and Therapy. Boca Raton, EL: CRC Press, 1990; 1-27.
72. Evans A, D'Angio G, Propert K, AndersonJ, Hann HWL. Prognostic factors in neuroblastoma. Cancer 1987;59:1853-9.
73. Brodeur G, PritchardJ, Berthold F, et al. Revisions of the international criteria for diagnosis, staging and response to treatment.J Clin Oncol 1993;ll:1466-77.
74. Carlsen N, Christensen I, Schroeder H, et al. Prognosüc factors in neuroblastomas treated in Denmark from 1943-1980. Cancer 1986:58:2726-35.
75. Shimada H, Chatten J, Newton W, et al. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastoma. J Natl Cancer Inst 1984:73:405-16.
76. Bolande RP. The spontaneous regression and cytodifferentiation of cancer in early life: The oncogenic grace period. Surv Synth Pathol Res 1985;4:296-311.
77. Bolande RP. Spontaneous regression of neuroblastoma. Pediatr Pathol 1990;10:195-206.
78. BeckwithJB, Perrin EV. In situ neuroblastomas: A contribution to the natural history of neural crest tumors. AmJ Pathol 1963:43:1089-1104.
79. Guin GH, Gilbert EF, Jones B. Incidental neuroblastoma in infants. AmJ Clin Pathol 1969;5: 126-36.
80. Kushner BH, Gilbert F, Helson L. Familial neuroblastoma. Case report, literature review and etiologic considerations. Cancer 1986:57:1887-93.
81. Chatten J, Voorhess ML. Familial neuroblastoma-report of a kindred with multiple disorders including neuroblastomas in four siblings. N EnglJ Med 1967;277:1230-6.
82. Gaisie G, Oh KS, Young LW. Coexistent neuroblastoma and Hirschsprung's disease. Another manifestation of neurocristopathy. Pediatr Radiol 1979;8:161-3.
83. Roshkow JE, Haller JO, Berdon WE, et al. Hirschsprung's disease, Ondine's curse, and neuroblastoma-manifestation of neurocristopathy. Pediatr Radiol 1988;19:45-9.
84. Clausen N, Andersson P, Tommerup N. Familial occurrence of neuroblastoma, von Recklinghausen's neurofibromatosis, Hirschsprung's aganglionosis andjaw-winking syndrome. Acta Paediatr Scandl 989;78:736-41.
85. Bolande RP, Towler WF. A possible relationship of neuroblastoma to von Recklinghausen's disease. Cancer 1970;26:162-75.
86. Dehner LP. Peripheral and central primitive neuroectodermal tumors. A nosologie concept seeking consensus. Arch Pathol Lab Med 1986;! 10:997-1005.
87. Coffin CM, Dehner LP. Peripheral neurogenic tumors of the soft tissues in children and adolescents: A clinicopathologic study of 139 cases. Pediatr Pathol 1989;9:387-407.
88. Tsokos M. Peripheral primitive neuroectodermal tumors. Perspect Pediatr Pathol 1992; 16:27-91.
89. DeLattre O, Zucman J, Melot T, et al. The Ewing family of tumors-a subgroup of small round cell tumors defined by specific chimeric transcripts. N EnglJ Med 1994;331:294-9.
90. Bravo EL. Pheochromocytoma: New concepts and future trends. Kidney Int 1991;40:544-56.
91. DeLellis RA, Wolfe HJ, Gagel RF, et al. Adrenal medullary hyperplasia. Am J Pathol 1976;83:177-96.
92. Khosla S, Patel VM, Hay ID, et al. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary carcinomas. J Clin Invest 1991;87:1691-9.
93. Williams ED. Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol 1966;19:114-8.
94. Tashjian AHJ, Melvin KE. Medullary carcinoma of the thyroid gland. N Engl J Med 1968; 279:279-83.
95. DeLellis RA. Multiple endocrine neoplasia syndromes revisited. Clinical, morphological and molecular features. Lab Invest 1995;72:494-505.
96. Byard RW, Thorner PS, Chan HSL, Griffiths AM, Cutz E. Pathological features of multiple endocrine neoplasia type 2B in childhood. Pediatr Pathol 1990;10:581-92.
97. Neumann HPH, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N EnglJ Med 1993;329:1531-8.
98. Hofstra RMW, Landsvater RM, Ceccherini I, et al. A mutation in the RETprotooncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994:67:375-6.
99. van Heyningen V. One gene-four syndromes. Nature 1994;367:319-20.
100. Santoro M, Rosati R, Grieco M, et al. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 1990;5:1595-8.
101. Chew SL, Lavender P, Jain A, et al. Absence of mutations in the MEN 2A region of the ret proto-oncogene in non-MEN 2A pheochromocytomas. Clin Endocrinol 1995;42:17-21.
102. Lindor NL, Honchel R, Khosla S, Thibodeau SN. Mutations in the RtTprotooncogene in sporadic pheochromocytomas. J Clin Endocrinol Metab 1995;80:627-9.
103. Nagao M, Ishizaka Y, Nakagawara A, et al. Expression of ret proto-oncogene in human neuroblastomas.jpnj Cancer Res 1990;81:309-12.
104. Pasini B, Borrello MG, Greco A. Loss of function of RET mutations causing Hirschsprung disease. Nat Genet 1995; 10:35-10.
105. Riccardi VM. von Recklinghausen's neurofibromatosis. N EnglJ Med 1981;305:1617-27.
106. Riccardi VM. Neurofibromatosis update. Neurofibromatosis 1989;2:284-91.
107. Riccardi VM. Neurofibromatosis: Past, present, and future. N EnglJ Med 1991;324:1283-5.
108. Riccardi VM, Womack JE, Jacks T. Neurofibromatosis and related tumors. Am J Pathol 1994; 145:994-1000.
109. Guttman DH. New insights in the neurofibromatoses. Curr Opin Neurol 1994;7:166-71.
110. Bolande RP. Neurofibromatosis-the quintessential neurocristopathy: Pathogenetic concepts and relationships. Adv Neurol 1981;29:66-75.
111. Cawthorn RM, O'Connell P, Buchberg AM. Identification and characterization of transcripts from the neurofibromatosis 1 region: The sequence and genomic structure of EV12 and mapping of other transcripts. Genomics 1990;7:555-65.
112. Ballester R, Marchuk D, Boguski M. The NF1 locus encodes a protein functionally related to mammalian GAP yeast IRA proteins. Cell 1990:63:851-9.
113. Johnson MR, DeClue JE, Felzmann S. Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function. Mol Cell Biol 1994;14:641-5.
114. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutated mutation in NF1. Nat Genet 1994;7:353-61.
115. Brannan Cl, Perkins AS, Vogel KS. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural-crest derived tissues. Genes Dev 1993;8: 1019-29.
116. Cardesa A, Ribalta T, von Schilling B, Palacin A, Mohr U. Experimental model of tumors associated with neurofibromatosis. Cancer 1989;63:1737-49.
117. Nakamura T, Hara M, Kasuga T. Transplacental induction of peripheral nervous tumor in the Syrian golden hamster by N-nitroso-N-ethylurea. A new model for von Recklinghausen's neurofibromatosis. Am] Pathol 1989:135:251-9.
118. Nakamura T, Nemoto T, Arai M, etal. Specific expression of the neurofibromatosis type 1 gene (NF1) in the hamster Schwann cell. AmJ Pathol 1994; 144:549-55.
119. Menon AG, Anderson KM, Riccardi VM, et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen's disease. Proc Nad Acad Sci USA 1990:87:5435-9.
120. Glover TW, Stein CK, Legius E, et al. Molecular and cytogenetic analysis of tumors in von Recklinghausen's disease. Genes Chromosom Cancer 1991:3:62-70.
121. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma support a tumour suppressor gene hypothesis. Nat Genet 1993; 3:122-6.
122. Bader ML, Miller RW. Neurofibromatosis and childhood leukemia. J Pediatr 1978;92:925.
123. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N EnglJ Med 1994; 330:597-601.
124. Stay EJ, Vawter G. The relationship between nephroblastoma and neurofibromatosis (von Recklinghausen's disease). Cancer 1977;39:1977.
125. Hope DG, MulvihillJ. Malignancy in neurofibromatosis. Adv Neurol 1981;29:33-56.
126. Xu W, Mulligan L, Ponder MA, Liu L, Smith BA, Ponder BAJ. Loss of NF1 alleles in pheochromocytomas from patients with type I neurofibromatosis. Genes Chromosom Cancer 1992;4: 337-42.
127. Witzleben CL, Landy RA. Disseminated neuroblastoma in a child with von Recldinghausen's disease. Cancer 1974;34:786-90.
128. Kushner BH, Hajdu SI, Helson L. Synchronous neuroblastoma and von Recklinghausen's disease. A review of the literature. J Clin Oncol 1985;3:117-20.
129. Qualman SJ, Green WR, Brovall C, Leventhal BG. Neurofibromatosis and associated neuroectodermal tumors: A congenital neurocristopathy. Pediatr Pathol 1986;5:65-78.
130. The I, Murthy AE, Hannigan GE, et al. Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat Genet 1993;3:62-6.
131. Seuanez H, Mane-Garzon F, Kolski R. Cardio-cutaneous syndrome (the Leopard syndrome): Review of the literature and a new family. Clin Genet 1976:9:266-76.
132. Schievink WI, Michels W, Mokri B, Piepgras DG, Perry HO. Brief report: A familial syndrome of arterial dissections with lentiginosis. N EnglJ Med 1995:332:576-9.
133. Abel EL. Fetal Alcohol Syndrome and Fetal Alcohol Effects. New York: Plenum, 1986.
134. Sulik KK, Johnston MC. Sequence of developmental alterations following acute ethanol exposure in mice: Cranio-facial features of the fetal alcohol syndrome. AmJ Anat 1983;166:2257-69.
135. Sulik KK. Normal and abnormal craniofacial embryogenesis. Birth Defects 1990;26:1-18.
136. Kotch LE, Sulik KK. Experimental fetal alcohol syndrome: Proposed pathogenic basis for a variety of associated facial and brain anomalies. AmJ Med Genet 1992;44:168-76.
137. Lammer E, Chen DT, Hoar RM, etal. Retinoic acid embryopathy. N EnglJ Med 1985:313:837-41.
138. Webster WS, Johnston MC, Lammer EJ, Sulik KK. Isotretinoin embryopathy and the cranial neural crest: An in vivo and in vitro study. J Craniofac Genet Dev Biol 1986;6:211-22.
139. Sulik KK, Johnston MC, Smiley SJ, Speight HS, Jarvis BE. Mandibulofacial dysostosis (Treacher Collins syndrome): A new proposal for its pathogenesis. AmJ Med Genet 1987:27:359-72.
140. Sulik KK, Johnston MC, Daft PA, Russell WK, Dehart DB. Fetal alcohol syndrome and DiGeorge anomaly: Critical ethanol exposure periods for craniofacial malformations as illustrated in an animal model. AmJ Med Genet 1986;2(Suppl):97-112.
141. Poswillo D. The etiology and pathogenesis of craniofacial deformity. Development 1988; 103(Suppl):207-12.
142. Sulik KK, Cook CS, Webster WS. Teratogens and craniofacial malformations. Development 1988; 103(Suppl):213-32.
143. Binder M. The teratogenic effects of abis(dichloroacetyl) diamine on hamster embryos. Aortic arch anomalies and the pathogenesis of the DiGeorge syndrome. AmJ Pathol 1985;118:179-93.
144. Nome AT. Effects of EDTA in newborn mice with special reference to neural crest cells. Anat Anz 1988;166:209-17.
145. Nome AT, Ono S. Exposure of newborn mice to adenosine causes neural crest dysplasia and tumor formation. Neurofibromatosis 1989:2:261-73.